Medullary Thyroid Carcinoma
📧 Sign up to get email alerts when something new happens for Medullary Thyroid Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-09-09Clinical Trial Update: Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer [Phase 3]
Phase 3 trial update on cabozantinib (XL184) for advanced medullary thyroid cancer provides efficacy results.
-
CLINICAL_TRIALS trial_result · 2014-08-11Clinical Trial Update: Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer [Phase 2]
Phase 2 trial evaluating the histone deacetylase inhibitor suberoylanilide hydroxamic acid (vorinostat) in patients with metastatic and/or l…
-
CLINICAL_TRIALS trial_result · 2014-05-06Clinical Trial Update: Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer [Phase 2]
Phase 2 trial of tanespimycin in patients with inoperable locoregionally advanced or metastatic thyroid cancer has completed with results po…
-
FDA approval · 2014-03-31FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for Caprelsa (vandetanib) submitted by Genzyme Corporation.
-
FDA approval · 2014-02-28FDA Approved: COMETRIQ — Supplemental Application (Exelixis, Inc.)
The FDA approved a supplemental application for COMETRIQ (cabozantinib) from Exelixis, Inc. This approval updates the drug's labeling.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2013-11-27FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for Caprelsa (vandetanib) submitted by Genzyme Corporation.
-
FDA approval · 2013-07-03FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation.
-
CLINICAL_TRIALS withdrawal · 2013-05-17Clinical Trial Update: Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma [Phase 2]
The Phase 2 clinical trial evaluating Sorafenib for advanced medullary thyroid carcinoma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2012-12-03Clinical Trial Update: The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer [Phase 1, Phase 2]
The document discusses an ongoing evaluation of CASAD for diarrhea related to medullary thyroid carcinoma across Phase 1 and Phase 2 trials.
-
FDA approval · 2012-11-29FDA Approved: COMETRIQ — Original Application (Exelixis, Inc.)
The FDA approved Cometriq (cabozantinib) from Exelixis as the original application for the treatment of metastatic medullary thyroid carcino…
-
FDA approval · 2012-10-09FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)
FDA approves a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation.
-
CLINICAL_TRIALS trial_result · 2012-08-31Clinical Trial Update: A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer [Phase 2]
Phase 2 study results are reported for ZD6474 (vandetanib, ZACTIMA) as monotherapy in hereditary medullary thyroid carcinoma, with results p…
-
CLINICAL_TRIALS trial_result · 2012-03-26Clinical Trial Update: An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer [Phase 3]
Phase 3 trial comparing vandetanib (ZD6474) to placebo in medullary thyroid carcinoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2011-11-11Clinical Trial Update: Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma [Phase 2]
A Phase II clinical trial evaluating a two-step radioimmunotherapy approach for medullary thyroid carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2011-06-15Clinical Trial Update: 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors [Phase 3]
This is a Phase 3 clinical trial update evaluating 123I‑MIBG scintigraphy for evaluating patients with suspected neuroendocrine tumors, incl…
-
FDA approval · 2011-04-06FDA Approved: CAPRELSA — Original Application (Genzyme Corporation)
FDA approved Caprelsa (vandetanib) from Genzyme for the treatment of unresectable, metastatic medullary thyroid carcinoma.
-
CLINICAL_TRIALS trial_result · 2010-07-07Clinical Trial Update: Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer [Phase 2]
A Phase 2 clinical trial evaluating 18F-DOPA PET imaging for medullary thyroid carcinoma has been terminated.